BBOT To Participate In The Jefferies Global Healthcare Conference In London

2025-11-03 04:17:08

(MENAFN- GlobeNewsWire - Nasdaq) SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in a presentation at the Jefferies Global Healthcare Conference on Monday, November 17, at 2:30 p.m. GMT.

A live webcast of the presentation will be accessible on the“Events” page of the BBOT website at . A replay of the webcast will be available for at least 90 days following the event.

About BBOT
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit LinkedIn

BBOT Contacts:

Investor Contact:
Heather Armstrong, Head of Investor Relations
BBOT
...

Media Contact:
Jake Robison
Inizio Evoke Comms
...

a-BridgeBio-Onc.png' referrerpolicy='no-referrer-when-downgrade' />

MENAFN03112025004107003653ID1110289257

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.